Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer.
Sara E. Barnato
No relevant relationships to disclose
Jacqueline Sara Jeruss
No relevant relationships to disclose
Kevin P. Bethke
No relevant relationships to disclose
Nora M. Hansen
No relevant relationships to disclose
Seema Ahsan Khan
No relevant relationships to disclose
Jamie H. Von Roenn
Consultant or Advisory Role - AstraZeneca
Steven T. Rosen
No relevant relationships to disclose
William John Gradishar
No relevant relationships to disclose
Kalliopi P. Siziopikou
No relevant relationships to disclose
Caitlin Meservey
No relevant relationships to disclose
Virginia G. Kaklamani
No relevant relationships to disclose